Moderna盘前跌超4%

Core Insights - Moderna's stock dropped over 4% in pre-market trading due to setbacks in its trial for a vaccine aimed at preventing birth defects [1] Company Summary - Moderna has paused the development of its vaccine for preventing birth defects following trial challenges [1]